Track market-moving stories before they get noisy

© Miha Creative / Shutterstock.com

The Number With oil now trading well below the $100 level (and seemingly poised to continue heading lower, after OPEC announced further production increases recently and recessionary concerns pick up), it’s unclear where certain oil stocks are headed.

One such name that’s on my radar right now just reported its Q1 2026 earnings in early May – Chevron (NYSE:CVX | CVX Price Prediction). With the company posting adjusted earnings of $1.41 per share against a $0.97 consensus (a 45.56% beat), there’s plenty to seemingly like about this company’s growth trajectory in a lower oil price environment.

Let’s dive into what these results mean for the average investor.

What It Means This recent earnings beat rested on operational strength as much as on crude prices. Chevron’s average Brent realization in the quarter came in at $81 per barrel versus $76 a year earlier, a modest tailwind. The volume story did the heavy lifting. Worldwide net oil-equivalent production reached 3,858 MBOED, up 15% year over year, powered by the company’s high-profile Hess acquisition. U.S. output cleared 2 million barrels per day for the third consecutive quarter, a company record.

Reported net income tells a noisier story at $2.21 billion, down 37.07% year over year, weighed by roughly $2.9 billion in unfavorable timing effects tied to derivatives and LIFO, a $360 million legal reserve, and a $223 million FX headwind. Strip those out and the operating engine is running hotter. Chevron returned $2.5 billion via buybacks in Q1, the 16th straight quarter of returning more than $5 billion to shareholders.

Market Reaction Chevron shares closed at $169.20 on July 2, 2026, up 13.12% year to date and 19.13% over the past year. Now, the stock’s recent price action has cooled, alongside oil prices which dipped. Over the past month, CVX stock is off nearly 10% as WTI retreated from May’s peak to around $68.50 per barrel on July 6. Peer Exxon Mobil (NYSE:XOM) and Suncor Energy (NYSE:SU) have seen similar downside moves, as investors gauge where oil prices could be headed over the medium-term.

Bull Case Chevron’s Q1 beat pairs cleanly with three durable levers. First, volume: production growth of 15% year over year is a rare figure for a supermajor, and the Hess integration is the reason U.S. barrels have crossed two million a day for three straight quarters.

Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and Chevron didn't make the cut. Grab the names FREE today.

Second, cost discipline is impressive, with Chevron delivering $1.5 billion in structural cost reductions in 2025, targeting $3 billion to $4 billion by the end of 2026.

Finally, the company’s capital return profile remains robust. Chevron returned $27.1 billion to shareholders in FY 2025, a 39th consecutive annual dividend increase, and a quarterly dividend of $1.78 per share that carries a yield near 4.17%.

CEO Mike Wirth framed the quarter this way: “Despite heightened geopolitical volatility and related supply disruptions, Chevron delivered solid first quarter performance, underscoring the resilience of our portfolio and the value of disciplined execution.”

Overall, Chevron’s forward P/E sits at 11, well below the trailing multiple, reflecting analyst expectations for higher earnings power as Hess barrels flow and cost programs land. Wall Street’s consensus target of $217.14 sits above current levels, with 18 buy or strong-buy ratings against one sell.

Bottom Line For long-term holders, Chevron’s 45.56% EPS beat is the tell. The company produced this metric all the while oil prices continued to sink below $70 per barrel. To me, that means the oil giants earnings engine is not in any way dependent on oil prices remaining in triple-digit territory. For those thinking long-term, that’s a big deal.

That said, it’s also true that volatility in commodity markets is a given. The catalyst worth watching is the structural cost target of $3 billion to $4 billion by year-end 2026. If Chevron hits it while Hess barrels compound, the $100 oil headline becomes optional to the investment case.

Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and Chevron didn't make the cut. Grab the names FREE today.

Contact [email protected] for any questions or corrections.

Ares Capital (ARCC) is trading at a multi-decade low valuation, and I'm upgrading the stock to a Strong Buy for its compelling risk/reward profile. ARCC's 10.3% dividend yield is well-supported by net investment income, with total annualized returns estimated at 18.4% through 2030. Concerns over ARCC's 70% software/adjacent exposure are mitigated by management's focus on foundational, sticky business infrastructure software.

WASHINGTON--(BUSINESS WIRE)--Easterly Government Properties, Inc. (NYSE: DEA) announced today that the Company will release its second quarter 2026 financial results on August 3, 2026. A conference call will be held Monday, August 3, 2026 at 11:00am Eastern time. The management team will review second quarter performance, discuss recent events and conduct a question-and-answer session. Attendees that would like to join the call and ask a question may register here to receive the dial-in numbers.

NEW YORK, July 07, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Lucid Group, Inc. (NASDAQ: LCID) between February 25, 2026 and April 13, 2026, inclusive (the “Class Period”), of the important July 28, 2026 lead plaintiff deadline.

SO WHAT: If you purchased Lucid securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Lucid class action, go to https://www.rosenlegal.com/cases/lucid-group-inc-2026/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than July 28, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) a supplier quality issue had significantly disrupted deliveries of the Lucid Gravity; (2) the foregoing was likely to, and did, have a material negative impact on Lucid’s business and financial results; (3) accordingly, the defendants had overstated the purported enhancements to Lucid’s manufacturing and delivery capabilities and overall operations; and (4) as a result, defendants’ public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Lucid class action, go to https://www.rosenlegal.com/cases/lucid-group-inc-2026/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

Contact Information:

        Laurence Rosen, Esq.
        Phillip Kim, Esq.
        The Rosen Law Firm, P.A.
        275 Madison Avenue, 40th Floor
        New York, NY 10016
        Tel: (212) 686-1060
        Toll Free: (866) 767-3653
        Fax: (212) 202-3827
        [email protected]
        www.rosenlegal.com

DraftKings shares are powering higher. What’s fueling DKNG momentum? What Is Driving DraftKings’ New DKeX Exchange?DraftKings is deepening its push into prediction markets with DKeX, a proprietary exchange built to support a more differentiated DraftKings Predictions experience and expand the range of event contracts available on its platform.

The rollout comes as DraftKings Predictions gains traction, with the company reporting about $3.4 billion in annualized consumer volume for the week ended June 21 and roughly $11.3 billion in annualized total trading volume. That scale is one reason traders are viewing DKeX as more than a routine product update, but as a move toward greater vertical integration.

The launch also comes as the prediction-markets space grows more competitive. Meta is reportedly developing a standalone app internally called "Arena," raising questions about whether new entrants could eventually pressure user engagement, pricing power and market share.

DraftKings Stock: Key Levels To WatchAt $26.98, the stock is trading above its 20-day SMA ($26.52), 50-day SMA ($25.37), and 100-day SMA ($24.41), which keeps the intermediate trend pointed up after the April swing low. The bigger-picture hurdle is still the 200-day SMA ($28.87), with shares trading 5.7% below that long-term trend line after a weaker 12-month run (down 32.85%).

MACD is the cleaner momentum read right now: it’s below its signal line with a negative histogram, which typically means upside pressure is cooling unless buyers can reassert control. In plain terms, MACD tracks trend momentum, and being below the signal line often shows the recent upswing is losing steam rather than accelerating.

Key Resistance: $30.00 — a round-number area that can act as an overhead supply zone as price works back toward longer-term resistance Key Support: $23.50 — a nearby floor that lines up with a prior buyer-defense zone and sits below the 50-day/100-day averages as a "trend break" tell What Is DraftKings and How Does It Operate?DraftKings got its start in 2012 as an innovator in daily fantasy sports, then expanded into online sports and casino gambling after the 2018 Supreme Court ruling that opened the door for state-by-state legalization. Today it generally holds the number-two or -three revenue share position across states where it competes, giving it scale benefits in a market where product depth and pricing can drive retention.

DraftKings Earnings Preview: What Analysts ExpectLooking further out, the next major catalyst for the stock arrives with the August 5, 2026 (estimated) earnings report.

EPS Estimate: 28 cents (Down from 38 cents YoY) Revenue Estimate: $1.56 Billion (Up from $1.51 Billion YoY) Valuation: P/E of 291.2x (Indicates premium valuation) Analyst Consensus & Recent Actions: The stock carries a Buy rating with an average price target of $35.13 (high $50.00, low $27.00) across 50 analysts. Recent analyst moves include:

Susquehanna: Positive (Lowers Target to $31.00) (July 1) Citizens: Market Outperform (Raises Target to $36.00) (June 25) Guggenheim: Buy (Maintains Target to $35.00) (June 24) DraftKings Benzinga Edge Rankings ExplainedBelow is the Benzinga Edge scorecard for DraftKings, highlighting its strengths and weaknesses compared to the broader market:

The Verdict: DraftKings’ Benzinga Edge signal reveals a premium-valued setup with only moderate growth support and still-weak momentum characteristics. For longer-term bulls, the cleaner technical tell is whether price can reclaim the 200-day area; for risk control, $23.50 is the nearby level that would start to undermine the current uptrend structure.

DraftKings Stock Price Action on TuesdayDKNG Stock Price Activity: DraftKings shares were up 2.75% at $26.93 at the time of publication on Tuesday, according to Benzinga Pro data.

Image: Shutterstock

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.

FCEL stock is tanking. See the chart and price action here. FuelCell Energy will grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock sold in the offering and intends to use the net proceeds for capex related to the expansion of manufacturing capacity to support growth and other general corporate purposes.

Shares fell more than 16% on the news, adding to the 12% loss from the regular trading session as traders took profits after a sharp run tied to the company’s recent data-center and financing headlines.

FCEL TechnicalsThe RSI is currently at 60.25, which is in neutral territory but suggests that the stock still has room to run before reaching overbought conditions. This level indicates that while there is positive momentum, traders should watch for any signs of reversal as the stock approaches higher levels.

MACD is above its signal line, reinforcing the bullish momentum in FuelCell’s stock. This suggests that the current trend is strong, and traders may look for buying opportunities as long as this condition holds.

Looking at the 12-month performance, FuelCell has skyrocketed by 372%, showcasing a remarkable uptrend over the past year. This impressive return highlights the stock’s strong bullish sentiment and the potential for continued growth in the longer term.

FCEL Price ActionFCEL Stock Price Activity: FuelCell Energy shares were down 15.22% at $22.01 during after-hours trading Tuesday, according to Benzinga Pro.

Photo: Shutterstock

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.

© Rawpixel.com / Shutterstock.com

Miller Tabak Chief Market Strategist Matt Maley believes investors should keep a close eye on two often-overlooked warning signs: the Japanese yen and South Korea’s KOSPI index. During CNBC’s Morning Call Sheet yesterday, he argued that a reversal in the popular yen carry trade and continued weakness in Korean stocks could signal broader trouble for global markets.

For investors with exposure to semiconductor equipment and chip stocks, those signals could prove especially important, as many of the industry’s largest customers are concentrated in Asia.

Why a Japanese Yen Reversal Could Rattle Global Markets Maley pointed to crowded positioning against the Japanese yen as a potential accelerant if the Bank of Japan is forced to defend its currency. “There’s some speculation that the BOJ will have to come in at some point and defend their currency. And we certainly know from the CFTC data that the short position in the yen is very, very large. So a lot of people are on one side of the boat. So if that situation starts to unwind and the carry trade starts to unwind, that could put some pressure on the markets.”

The USD/JPY rate stood at 161.93 as of July 6, 2026, and the VIX closed at 15.81 on July 3, 2026, sitting in the 22.6th percentile of its 12-month distribution and well below the 18.088 average.

The Overseas Market Maley Says Investors Should Watch Closely On Korea, Maley reached back a quarter-century for his analogy. “I just note that in 2000, when the bubble burst in 2000, the KOSPI was the first one to go down several months in advance of the rest of the world. So it’s important to keep a close eye on that.” He added that the KOSPI has been very choppy over the last month, with Samsung set to report earnings this week and SK Hynix’s ADR set to begin trading in the U.S. Both are memory chipmakers and major customers of U.S.-listed equipment and design names that investors can trade.

Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and ASML didn't make the cut. Grab the names FREE today.

Why Lam Research Could Feel the Impact First Lam Research (NASDAQ:LRCX | LRCX Price Prediction) is arguably one of the companies that would feel the biggest impact of negative KOSPI developments. In its March 2026 quarter, South Korea contributed $1.344 billion, or 23% of revenue, matching Taiwan and trailing only China’s $1.986 billion. Combined Asia-Pacific exposure sits at roughly 87% of the $5.841 billion quarterly total. CEO Tim Archer noted “Lam delivered record revenue and EPS in the March quarter as AI-driven demand reshapes the semiconductor industry,” while the 10-Q explicitly flags trade regulations, export controls, and geopolitical tensions as material risks. Shares fell 12.55% in the week ending July 2, 2026, though the stock remained up 105.67% year to date.

Samsung’s Earnings Could Be a Major Test for ASML ASML Holding (NASDAQ:ASML) sells the EUV lithography tools that Samsung and SK Hynix rely on for advanced DRAM. Q1 2026 delivered revenue of $10.34 billion and EPS of $8.43, with a gross margin of 53.0%, and management raised full-year guidance to €36 billion to €40 billion. CEO Christophe Fouquet noted, “The semiconductor industry’s growth outlook continues to solidify, driven by ongoing AI-related infrastructure investments,” though guidance explicitly accounts for export-control outcomes. Year-end 2025 backlog stood at $45.06 billion. Choppy Korean chip demand would show up here first in orders and push-outs.

Why Qualcomm Faces More Than One Headwind Qualcomm (NASDAQ:QCOM) already shows the strain Maley is warning about. Fiscal Q2 2026 handset revenue fell 13% year over year to $6.024 billion on memory supply constraints and Chinese OEM softness, and Q3 guidance implies further sequential decline at $9.2 billion to $10.0 billion in revenue and $2.10 to $2.30 in non-GAAP EPS. CEO Cristiano Amon framed the pivot toward “our entry into the data center, where a leading hyperscaler custom silicon engagement is on track for initial shipments later this calendar year.” The stock trades at a forward P/E of about 16, and management has flagged China concentration as a standing risk in every recent filing.

What to Watch Next Maley’s broader message is that market risks may first appear overseas before reaching U.S. stocks. A sharp reversal in the yen carry trade or continued weakness in South Korea’s KOSPI could signal tightening liquidity and softer demand for semiconductor equipment, creating headwinds for companies such as Lam Research, ASML, and Qualcomm. While none of these indicators guarantees a broader market downturn, Maley believes investors should monitor them in the weeks ahead.

Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and ASML didn't make the cut. Grab the names FREE today.

Contact [email protected] for any questions or corrections.

NEW YORK, July 07, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Zoetis Inc. (NYSE: ZTS) between January 14, 2025 and May 6, 2026, inclusive (the “Class Period”), of the important July 27, 2026 lead plaintiff deadline.

SO WHAT: If you purchased Zoetis securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Zoetis class action, go to https://rosenlegal.com/cases/zoetis-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than July 27, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made false and/or misleading statements and touted growing market share, strong veterinarian adoption, and accelerating sales growth across Zoetis’ flagship Companion Animal products and/or failed to disclose that: (1) veterinarian prescription growth and adoption of Zoetis’ Librela, a canine pain treatment, were sharply weakening as clinicians became more cautious following FDA safety warnings concerning serious neurological complications in dogs; (2) Zoetis’ Simparica Trio was losing significant market share to a lower priced competing canine parasiticide with broader indicated use in a slowing overall market; and (3) Zoetis’ dermatology products, Apoquel and Cytopoint, were losing substantial market share to a newly launched competing canine treatment. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Zoetis class action, go to https://rosenlegal.com/cases/zoetis-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

Contact Information:

        Laurence Rosen, Esq.
        Phillip Kim, Esq.
        The Rosen Law Firm, P.A.
        275 Madison Avenue, 40th Floor
        New York, NY 10016
        Tel: (212) 686-1060
        Toll Free: (866) 767-3653
        Fax: (212) 202-3827
        [email protected]
        www.rosenlegal.com

LONG BEACH, Calif., July 07, 2026 (GLOBE NEWSWIRE) -- Rocket Lab Corporation (Nasdaq: RKLB), a global leader in launch services and space systems, today announced mission success for its role in the U.S. Space Force’s (USSF) VICTUS HAZE mission.

This historic mission required Rocket Lab to design, build, and test a Pioneer spacecraft for the USSF, launch it on Electron within 24 hours’ notice, commission the spacecraft within 72 hours, and then conduct complex rendezvous and proximity operations (RPO) on orbit within 84 hours to pursue, monitor, approach, and photograph another target satellite in a demonstration of a rapid threat-response scenario.

Rocket Lab successfully completed all mission phases faster than the deadlines set by the Space Force, setting records and delivering new standards in responsive space.

Responsive Launch: On June 19th, Rocket Lab launched the VICTUS HAZE mission just 16 hours and 42 minutes after receiving the Notice To Launch from the Space Force - the fastest response time ever for a Tactically Responsive Space (TacRS) mission.Spacecraft Commissioning: Completed within 38 hours – more than 30 hours ahead of the Space Force’s 72-hour deadline – Rocket Lab’s spacecraft operation team methodically activated and verified all of Pioneer’s systems including power, communications, and attitude control, ensuring the satellite was fully operational and ready to begin its tactical space domain awareness mission. RPO Operations: Completed in less than 59 hours – 25 hours ahead of the Space Force’s 84-hour deadline. Rocket Lab’s Pioneer spacecraft performed a series of complex orbital maneuvers to pursue, monitor, approach, and photograph a target satellite on orbit. Throughout operations, Rocket Lab maintained continuous tracking of the target spacecraft, demonstrating precision navigation and control capabilities essential for space domain awareness operations. While traditional missions have relied on separate contractors for rockets, satellites, and operations in space, Rocket Lab is delivering all three for VICTUS HAZE – the first time a single prime contractor has provided an entire all-in-one mission for the TacRS program.

Rocket Lab founder and CEO, Sir Peter Beck, says: “Rocket Lab has set the new standard in responsive space with VICTUS HAZE. Delivering a fully integrated and complete mission capability when the clock is ticking is a proud moment for the Rocket Lab team in a long history of delivering mission success for the United States and its allies. Now that the primary mission is complete, we look forward to continuing to push Pioneer on orbit under new and complex Space Force task orders to deliver new capabilities.”

Deployed by the USSF’s Space Systems Command (SSC), led by the Space Safari Program Office, in partnership with the Defense Innovation Unit (DIU), VICTUS HAZE is a Tactically Responsive Space (TacRS) mission generating the vital data, technology, and real-world operational experience needed to make that rapid response a repeatable reality.

With the threshold RPO demonstration now successfully completed, Rocket Lab will continue to operate the Pioneer spacecraft on orbit for several more months to prove out additional advanced RPO tactics, techniques, and procedures tasked by Space Safari.

Rocket Lab’s continued successful delivery of responsive space missions and increasingly complex RPO mission objectives for the USSF reinforces the Company’s reputation as a trusted partner capable of executing the most challenging and time-critical missions for national security.

Rocket Lab Media Contact
Murielle Baker
[email protected]

About Rocket Lab
Rocket Lab is a leading space company providing launch services, spacecraft, payloads, and satellite components to commercial, government, and national security customers. Rocket Lab's Electron rocket is the world's most frequently launched orbital small rocket; its HASTE rocket provides hypersonic test launch capability for the U.S. government and allied nations; and its Neutron launch vehicle in development will unlock medium launch for constellation deployment, national security, and exploration missions. Rocket Lab is publicly listed on the Nasdaq stock exchange (RKLB). Learn more at www.rocketlabcorp.com

Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). All statements contained in this press release other than statements of historical fact, including, without limitation, statements regarding our launch and space systems operations, launch schedule and window, safe and repeatable access to space, Neutron development, operational expansion and business strategy, are forward-looking statements. The words “believe,” “may,” “will,” “estimate,” “potential,” “continue,” “anticipate,” “intend,” “expect,” “strategy,” “future,” “could,” “would,” “project,” “plan,” “target,” and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements use these words or expressions. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including but not limited to the factors, risks and uncertainties included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025, as such factors may be updated from time to time in our other filings with the Securities and Exchange Commission (the “SEC”), accessible on the SEC’s website at www.sec.gov and the Investor Relations section of our website at https://investors.rocketlabcorp.com which could cause our actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.

July 07, 2026 16:15 ET  | Source: Wave Life Sciences USA, Inc.

CAMBRIDGE, Mass., July 07, 2026 (GLOBE NEWSWIRE) -- As previously announced, Wave Life Sciences Ltd. (NASDAQ: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health (“Wave” or “Wave Life Sciences”), has obtained the requisite shareholder approval required in connection with its proposed redomiciliation (“Redomiciliation”) to the United States by way of the implementation of a statutory procedure known as a scheme of arrangement under Section 210 of the Companies Act 1967 of Singapore (the “Scheme of Arrangement”). The Scheme of Arrangement remains subject to approval by the High Court of the Republic of Singapore (the “Singapore Court”).

Wave has made an application to the Singapore Court to approve the Scheme of Arrangement, as filed in HC/SUM 2058/2026 in HC/OA 434/2026 in the Singapore Court on July 1, 2026 (Singapore Time), and the application has been directed to be heard before the Singapore Court on July 14, 2026 at 2:30 pm (Singapore Time), at Chamber 2A of the Supreme Court of Singapore at 1 Supreme Court Lane, Singapore 178879. The Singapore Court has directed that any affidavits in response to the application must be submitted to the Singapore Court by 4:00 pm (Singapore Time) on July 8, 2026, and that any written submissions and bundles of authorities must be filed with and tendered to the Singapore Court by 4:00 pm (Singapore Time) on July 10, 2026.

A copy of the materials filed with the application and the related directions provided by the Singapore Court will be made available under the Corporate Governance section of our Investor Relations website.

About Wave Life Sciences

Wave Life Sciences (Nasdaq: WVE) is a biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health. Wave’s PRISM® platform combines multiple modalities, chemistry innovation and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and common disorders. Its toolkit of RNA-targeting modalities, including RNAi (SpiNA) and RNA editing (AIMers), provides Wave with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology. Wave’s pipeline is focused on its obesity (WVE-007), alpha-1 antitrypsin deficiency (WVE-006) and PNPLA3 I148M liver disease (WVE-008) programs, and also includes clinical programs in Duchenne muscular dystrophy and Huntington’s disease, as well as several preclinical programs utilizing the company’s versatile RNA medicines platform. Driven by the calling to “Reimagine Possible,” Wave is leading the charge toward a world in which human potential is no longer hindered by the burden of disease. Wave is headquartered in Cambridge, MA. For more information on Wave’s science, pipeline and people, please visit www.wavelifesciences.com and follow Wave on X and LinkedIn.

Cautionary Note Regarding Forward-Looking Statements

Some of the statements included in this announcement may include “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, in particular, statements about our expectations regarding the change of the parent company of the group from a Singapore company to a Delaware corporation. These statements include, but are not limited to, statements that address our expected future business and statements about the Redomiciliation and other statements identified by words such as “will”, “expect”, “believe”, “anticipate”, “estimate”, “should”, “intend”, “plan”, “potential”, “predict”, “project”, “aim”, and similar words, phrases or expressions. These forward-looking statements are based on current expectations and beliefs of the management of Wave Life Sciences, as well as assumptions made by, and information currently available to, such management, current market trends and market conditions and involve risks and uncertainties, many of which are outside Wave Life Sciences’ and management’s control, and which may cause actual results to differ materially from those contained in forward looking statements. Accordingly, you should not place undue reliance on such statements.

Particular uncertainties that could materially affect future results include risks associated with the Redomiciliation, including our ability to obtain shareholder and Singapore High Court approvals and satisfy other closing conditions to the completion of the Redomiciliation within the expected timeframe or at all; our ability to realize the expected benefits from the Redomiciliation; the occurrence of difficulties or material timing delays in connection with the Redomiciliation, including any unanticipated costs in connection therewith; any delays, challenges and expenses associated with receiving governmental and regulatory approvals; changes in tax laws, tax treaties or tax regulations or the interpretation or enforcement thereof by the tax authorities in Singapore, the United States and other jurisdictions following the Redomiciliation; our critical accounting policies; the ability of our preclinical studies to produce data sufficient to support the filing of global clinical trial applications and the timing thereof; our ability to continue to build and maintain the company infrastructure and personnel needed to achieve our goals; the clinical results and timing of our programs, which may not support further development of our product candidates; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials; our effectiveness in managing current and future clinical trials and regulatory processes; the success of our platform in identifying viable candidates; the continued development and acceptance of nucleic acid therapeutics as a class of drugs; our ability to demonstrate the therapeutic benefits of our stereopure candidates in clinical trials, including our ability to develop candidates across multiple therapeutic modalities; our ability to obtain, maintain and protect intellectual property; our ability to enforce our patents against infringers and defend our patent portfolio against challenges from third parties; our ability to fund our operations and to raise additional capital as needed; competition from others developing therapies for similar uses; and any impacts on our business as a result of or related to any local and global health epidemics, geopolitical conflicts, global economic uncertainty, the impact of tariffs and changes in economic policies, volatility in inflation, volatility in interest rates or market disruptions on our business.

The foregoing review of important factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are set forth in our definitive proxy statement filed on May 7, 2026 and our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and the other documents that we file with the SEC, including under the heading “Risk Factors” in our most recent Annual Report on Form 10-K. You may obtain copies of these documents as described under the heading “Additional Information and Where to Find It.”

Our filings with the Securities and Exchange Commission (“SEC”), which you may obtain without charge at the SEC’s website at http://www.sec.gov, discuss some of the important risk factors that may affect our business, results of operations and financial condition. We undertake no intent or obligation to publicly update or revise any of these forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Investors:

James Salierno
Director, Investor Relations
+1 617-949-4043
[email protected]

Media:

Katie Sullivan
Senior Director, Corporate Communications
+1 617-949-2936
[email protected] 

HomeStock IdeasLong IdeasFinancials 

SummaryBerkshire Hathaway Inc. is poised for an upward breakout after a multi-year consolidation, supported by recent technical and fundamental catalysts.Optimism about BRK.B stems from a strong 2026 P/C insurance market outlook, elevated treasury yields, and renewed capital deployment under Greg Abel, including the $6.8B Taylor Morrison acquisition.Technical signals—such as a breakout above key resistance levels, rising RSI, and bullish price-volume action—reinforce the near-term upside potential.Despite a premium forward P/E of 24.41x, BRK.B trades at a discount on EV-based metrics, supporting a favorable risk/reward profile toward reclaiming its $540 record high.Looking for a helping hand in the market? Members of Envision Early Retirement get exclusive ideas and guidance to navigate any climate. Learn More » HYWARDS/iStock via Getty Images

BRK stock has been in a multi-year consolidation I have been feeling lukewarm about Berkshire Hathaway Inc. (BRK.A) (BRK.B) and rated it as a Hold in the past year or so. For example, my

20.75K Followers

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Key Takeaways MCHP is positioned to gain from rising mixed-signal MCU demand across industrial and auto markets.Mixed-signal MCUs made up nearly 50% of fiscal 2026 revenue, supporting long-term growth.Bookings improved, book-to-bill stayed above one and April marked the strongest month in nearly four years. Microchip Technology (MCHP - Free Report) is well positioned to benefit from the growing demand for mixed-signal microcontrollers (MCUs), leveraging its expanding footprint in industrial embedded control, broad product portfolio and total system solutions strategy. Mixed-signal MCUs remain the company's largest product category, accounting for nearly 50% of fiscal 2026 revenues, highlighting their importance to long-term growth.

The company is witnessing renewed demand across its key MCU-driven markets, including industrial automation, automotive, aerospace & defense, communications and AI-enabled data centers. MCHP management noted that innovation-driven growth has resumed as customers restart new product development after working through excess inventories. These new designs increasingly require intelligent mixed-signal MCUs capable of integrating analog, connectivity, security and real-time control functions into a single platform. Microchip highlighted particularly strong innovation activity in industrial automation, automotive, aerospace & defense and data center applications.

Microchip’s leadership in mixed-signal MCUs is further strengthened by its Total System Solutions strategy. Rather than selling standalone microcontrollers, the company bundles MCUs with analog ICs, power management, connectivity, timing, security and FPGA products, increasing content per design win and making its platforms more attractive for customers. The company continues to maintain strong attach rates while expanding reference designs that encourage customers to adopt more Microchip components within a single system, supporting higher long-term revenue per application.

The company’s diversified customer base and long product life cycles also provide resilience. Mixed-signal MCU demand is recovering across thousands of customers as inventories normalize, while bookings have strengthened, book-to-bill remains above one, and April represented the strongest booking month in nearly four years. Microchip expects nearly all business units, including its microcontroller franchise, to participate in the ongoing recovery, supported by broad-based demand across industrial, automotive, aerospace & defense and data center markets.

MCHP Faces Tough CompetitionMicrochip is facing significant competition from the likes of Texas Instruments (TXN - Free Report) and Analog Devices (ADI - Free Report) .

Texas Instruments competes directly with Microchip by expanding its embedded processing portfolio around MCU targeting industrial, automotive and power applications. Management emphasized that Texas Instruments is shifting its embedded business toward a broader MCU portfolio with integrated analog peripherals, application-specific MCUs, motor control, power conversion, connectivity and radar capabilities. The planned acquisition of Silicon Labs further strengthens its wireless MCU offerings, particularly for industrial IoT, giving Texas Instruments a broader embedded portfolio that competes directly with Microchip's mixed-signal MCU franchise.

Analog Devices competes with Microchip in embedded processing by combining high-performance mixed-signal technologies with embedded intelligence for industrial and automotive applications. Rather than offering standalone MCUs, Analog Devices integrates sensing, signal-chain, power management, connectivity and software to enable edge intelligence for digital factories, robotics, healthcare and automotive systems. This allows ADI to address complex embedded control applications where precision analog performance and real-time processing are critical, competing directly with Microchip's higher-end mixed-signal MCU portfolio.

MCHP’s Share Price Performance, Valuation & EstimatesShares of Microchip have appreciated 37.4% year to date, outperforming the broader Zacks Computer and Technology sector’s rise of 16.6%.

MCHP Stock’s Price Performance
Image Source: Zacks Investment Research

The MCHP stock is trading at a premium, with a forward 12-month price/earnings of 26.35X compared with the broader sector’s 24.98X. Microchip has a Value Score of D.

MCHP’s Valuation
Image Source: Zacks Investment Research

The Zacks Consensus Estimate for Microchip’s fiscal 2027 earnings is currently pegged at $3.09 per share, up by a penny over the past 30 days, suggesting 88.4% growth from the fiscal 2026’s reported figure.

Microchip currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

New York, New York and New Orleans, Louisiana--(Newsfile Corp. - July 7, 2026) - Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have until August 28, 2026 to file lead plaintiff applications in a securities class action lawsuit against Hub Group, Inc. ("Hub" or the "Company") (NASDAQ: HUBG), if they purchased or otherwise acquired the Company's securities between April 28, 2023, and May 11, 2026, inclusive (the "Class Period"). This action is pending in the United States District Court for the Northern District of Illinois.

Cannot view this video? Visit:
https://www.youtube.com/watch?v=aqHdidapNT0

What You May Do

If you purchased securities of Hub as above and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email ([email protected]), or visit https://www.ksfcounsel.com/cases/nasdaqgs-hubg/ to learn more. If you wish to serve as a lead plaintiff in this class action, you must petition the Court by August 28, 2026.

>>>CLICK HERE for more information

About the Lawsuit

Hub Group and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.

On February 5, 2026, the Company disclosed that its financial statements and reports for the first three quarters of 2025 should not be relied upon due to "an error that resulted in the understatement of purchased transportation costs and accounts payable in the first nine months of 2025" and that it planned to restate the statements. On this news, the price of Hub Group shares fell approximately 18%, from $51.33 per share on February 5, 2026 to $41.96 on February 6, 2026.

Then, on May 12, 2026, the Company disclosed that it had "identified certain transactions that were prematurely or incorrectly recognized or not adequately supported," causing its 2023 and 2024 annual reports filed with the SEC to be "materially misstated," such that they should no longer be relied upon, and "expect[ed] to conclude that it did not maintain effective disclosure controls and procedures and internal control over financial reporting for each of the years ended December 31, 2024 and 2023." On this news, the price of Hub Group shares fell an additional 13%, from $41.86 per share at close on May 11, 2026 to $36.62 on May 12, 2026.

The case is Lawler v. Hub Group, Inc., et al, 26-cv-07596.

>>>To Learn More, Click HERE

About Kahn Swick & Foti, LLC

KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation's premier boutique securities litigation law firms. This past year, KSF was ranked by SCAS among the top 10 firms nationally based upon total settlement value. KSF serves a variety of clients, including public and private institutional investors, and retail investors - in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, Delaware, California, Louisiana, Chicago, and a representative office in Luxembourg.

TOP 10 Plaintiff Law Firms - According to ISS Securities Class Action Services

To learn more about KSF, you may visit www.ksfcounsel.com.

>>>For More Information about the case, Click HERE

CONNECT WITH US: Facebook || Instagram || YouTube || TikTok || LinkedIn

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/304293

Source: Kahn Swick & Foti, LLC

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

StepStone Group (STEP) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

New York, New York--(Newsfile Corp. - July 7, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds sellers of common stock of ChampionX Corporation (NASDAQ: CHX) between February 29, 2024 and April 1, 2024, inclusive (the "Class Period"), of the important July 14, 2026 lead plaintiff deadline.

SO WHAT: If you sold ChampionX common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the ChampionX class action, go to https://rosenlegal.com/cases/championx-corporation/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than July 14, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period failed to disclose material information, which artificially deflated the price of ChampionX common stock. On February 29, 2024, ChampionX received an unsolicited non-public offer from Schlumberger Limited to purchase all the outstanding shares of ChampionX for $36.70 per share. On March 7, 2024, Schlumberger raised its offer to $37.80 per share. The lawsuit alleges that while these offers were on the table and unknown to the investing public, ChampionX was repurchasing its common stock at market prices significantly below the prices offered by Schlumberger. ChampionX had an obligation to disclose that it had received a formal acquisition offer from Schlumberger or abstain from purchasing ChampionX stock from unsuspecting investors. During the Class Period, ChampionX's average stock price was $33.32 per share. On Tuesday, April 2, 2024, during pre-market hours, ChampionX disclosed the merger with Schlumberger. The merger eventually closed on July 16, 2025, with Schlumberger acquiring ChampionX for $40.58 per share.

To join the ChampionX class action, go to https://rosenlegal.com/cases/championx-corporation/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/304305

Source: The Rosen Law Firm PA

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

Key Takeaways APP delivered record Q1 2026 revenues of $1.84 billion, up 59% year over year.AppLovin posted an 85% adjusted EBITDA margin and a 65% net margin in its latest quarter.APP trades at premium valuation multiples, supporting a hold stance despite strong fundamentals. Despite delivering strong operational performance, AppLovin (APP - Free Report) has seen its stock decline roughly 19% year to date. The weakness reflects shifting market sentiment toward high-growth technology stocks rather than any visible deterioration in the company’s fundamentals. While investors have grown cautious about valuation and broader macroeconomic uncertainty, AppLovin continues to execute at a remarkably high level.

                                                                 Image Source: Zacks Investment Research

The company remains one of the fastest-growing names in digital advertising, supported by artificial intelligence-driven ad optimization, expanding monetization capabilities and improving profitability. As the stock trades well below its recent highs, investors may need to determine whether the recent correction reflects a fundamental concern or simply a disconnect between price action and business performance.

AI-Powered Advertising Continues to Drive APP’s Revenue GrowthAppLovin’s growth story remains firmly intact, with demand for its AI-powered advertising and app monetization platform continuing to accelerate.

Quarterly revenues climbed steadily from $406 million in the second quarter of 2023 to nearly $1 billion by the fourth quarter of 2024. The momentum strengthened further throughout 2025, with quarterly revenues consistently exceeding $1 billion while maintaining sequential growth.

The company carried that momentum into the first quarter of 2026, reporting record quarterly revenues of $1.84 billion, representing an impressive 59% year-over-year increase.

This sustained expansion reflects increasing adoption of AppLovin’s AI-enhanced advertising solutions, particularly improvements driven by its Axon platform. The company has also broadened its reach beyond its traditional gaming customer base into larger e-commerce and digital advertising markets, creating new opportunities for long-term expansion.

As advertisers increasingly rely on AI-powered targeting, campaign optimization and monetization tools to improve returns on advertising spend, AppLovin continues to strengthen its position within one of the fastest-growing segments of the digital advertising industry.

Margin Expansion Is Becoming APP’s StrengthAlthough rapid revenue growth continues to attract investor attention, AppLovin’s profitability may represent its greatest long-term strength.

The company is increasingly generating revenue from higher-margin software offerings, allowing a much larger percentage of incremental sales to flow directly to the bottom line. This favorable business mix, combined with disciplined cost management, has significantly improved operating efficiency over the past several quarters.

During its latest reported quarter, AppLovin delivered an adjusted EBITDA margin of 85%, expanding 100 basis points from the prior-year period. Net margin improved even more dramatically, rising 1,500 basis points to 65%.

These figures demonstrate that AppLovin is not merely growing rapidly; it is scaling efficiently. Many technology companies can deliver strong top-line expansion, but far fewer can convert that growth into substantial profitability.

The company’s operating leverage suggests its business model becomes increasingly profitable as revenues continue to expand, reinforcing the quality and durability of its earnings profile.

Analyst Projections Signal Fundamental StrengthAnalyst expectations reflect continued optimism. The Zacks Consensus Estimate for second-quarter 2026 earnings is pegged at $3.72 per share, indicating a 65% increase from the year-ago period. Revenue for the same quarter is expected to reach $1.94 billion, indicating 54% year-over-year growth. Looking further ahead, full-year 2026 earnings are projected to increase 59%, with 2027 earnings expected to rise an additional 32%. Revenues are also expected to increase 42% in 2026 and 29.5% in 2027. These projections underscore confidence in the company’s monetization engine and its ability to deliver strong earnings amid digital ad market expansion.

APP Valuation Appears ElevatedAPP currently trades at a forward P/E multiple of 29.29, noticeably above the industry average of 22.11.

                                                                    Image Source: Zacks Investment Research

Its forward price-to-sales ratio of 19.21 also stands far above the industry benchmark of 2.89, indicating that investor expectations for future growth remain extremely aggressive.

                                                                     Image Source: Zacks Investment Research

When stocks trade at premium valuation levels, even modest growth slowdowns or softer guidance can lead to significant multiple compression. Consequently, APP shares could remain vulnerable if market sentiment shifts or expectations are revised lower.

Comparing APP With Major U.S. Advertising Technology RivalsThe Trade Desk (TTD - Free Report) operates a demand-side advertising platform centered around programmatic advertising and advanced audience targeting capabilities. Although The Trade Desk benefits from strong exposure to premium advertising brands, its profitability profile tends to be more cyclical and sensitive to broader advertising spending trends compared with AppLovin. While TTD prioritizes scale and reach, AppLovin remains more focused on performance optimization and monetization efficiency.

Unity Software (U - Free Report) also maintains exposure to digital advertising through its real-time 3D platform and monetization offerings. However, Unity Software’s advertising operations remain closely connected to developer ecosystems and have historically demonstrated greater volatility. Unlike AppLovin, Unity Software continues to balance profitability objectives alongside growth expansion, making AppLovin’s consistent margin profile a notable competitive advantage among peers.

Hold Rating Appears AppropriateAppLovin continues to execute exceptionally well, supported by robust demand for its AI-powered advertising platform, expanding profitability, and favorable long-term growth prospects. The company has consistently demonstrated its ability to scale efficiently while strengthening its competitive position across the digital advertising ecosystem. However, much of this optimism appears reflected in the stock's premium valuation, leaving limited room for disappointment if growth moderates or market sentiment weakens. Although the long-term outlook remains compelling, the current risk-reward profile suggests investors should adopt a wait-and-watch approach. APP appears appropriately rated as a Hold while investors monitor future execution and valuation trends.

APP carries a Zacks Rank #3 (Hold) at present. You can see the complete list of today’s Zacks Rank #1 (Strong Buy) stocks here.

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In PicS To Contact Him Directly To Discuss Their Options

If you purchased or acquired PicS Class A Common stock in and/or traceable to PicS' January 30, 2026 initial public offering ("IPO") and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

[You may also click here for additional information]

New York, New York--(Newsfile Corp. - July 7, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against PicS N.V. ("PicS" or the "Company") (NASDAQ: PICS) and reminds investors of the August 4, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.

As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) PicS N.V. had conducted an evaluation of its credit evaluation procedures in December 2025 and determined that such procedures were deficient and in need of enhancement; (2) as a result of the new procedures PicS N.V. had implemented in December 2025, PicS N.V. had reclassified approximately R$590 million of exposures previously classified as Stage 2 to Stage 3, leading to an incremental ECL charge of R$88 million in the three months ended December 31, 2025; (3) PicS N.V. had experienced a heightened, but unreported, Stage 3 formation rate of more than 7% in the fourth quarter of 2025 that deviated substantially from the historical results and trends provided in the offering documents; (4) the IPO's offering documents had materially overstated the quality and ability of PicS N.V.'s credit models and user data to inform PicS N.V.'s underwriting practices and to allow PicS N.V. to timely and effectively monitor, assess, and identify adverse credit events, credit risks, and credit deterioration across its portfolio; and (5) PicS N.V. suffered from degradations in customer credit quality and heightened risks of default and loan impairment as a result of its entrance into materially riskier business lines leading up to the IPO, resulting in undisclosed adverse financial and operational trends such as heightened incidents of default, which predated the IPO and were internally projected by PicS N.V. to continue to worsen following the IPO, materially impairing PicS N.V.'s business, operations, and financial results.

On or around January 29, 2026, PicPay conducted its initial public offering ("IPO"), selling 22.86 million Class A common shares priced at $19.00 per share.

Then, on March 18, 2026, PicPay released its fourth quarter 2025 financial results and revealed that, as part of the Company's "annual review of expected credit loss parameters," it had made several "enhancements" to its Expected Credit Loss ("ECL") calculations, and "implemented a stricter policy to accelerate the classification of renegotiated non-performing exposures from Stage 2 to Stage 3." Consequently, "R$590 million of Stage 2 portfolio balances were reclassified to Stage 3, resulting in an ECL increase of R$88 [$17.56 million USD]." Stage 3 is the Company's highest risk category for its credit portfolio.

On this news, PicPay's stock price fell $3.56 per share, or 22.5%, to close at $12.27 per share on March 19, 2026.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.

Faruqi & Faruqi, LLP also encourages anyone with information regarding PicS' conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

To learn more about the PicS N.V. class action, go to www.faruqilaw.com/PICS or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Follow us for updates on LinkedIn, on X, or on Facebook.

Frequently Asked Questions (FAQ) for Investors Regarding the PicS N.V. Securities Class Action Lawsuit:

What is the PicS N.V. securities fraud lawsuit about?

The PicS N.V. securities fraud lawsuit is a federal securities class action alleging that PicS N.V. (NASDAQ: PICS) and its executives made false and misleading statements to investors in connection with the Company's January 30, 2026 IPO by concealing that the Company had already identified deficiencies in its credit evaluation procedures in December 2025, had reclassified approximately R$590 million of exposures from Stage 2 to Stage 3 (its highest credit risk category) resulting in an incremental expected credit loss charge of R$88 million, and was experiencing a Stage 3 formation rate exceeding 7% in Q4 2025 — a significant deviation from the historical trends presented in the IPO's offering documents. As the truth emerged on March 18, 2026, when PicS disclosed these credit portfolio deteriorations as part of its Q4 2025 financial results, PICS shares fell $3.56 per share, or 22.5%, to close at $12.27 — well below the $19.00 IPO price — causing significant losses for investors.

Who may be eligible to participate in the PicS N.V. class action lawsuit?

Investors who purchased PicS N.V. (PICS) Class A common stock in and/or traceable to the Company's January 30, 2026 initial public offering and suffered financial losses may be eligible to participate in the PicS securities class action. Participation as a class member does not require taking any affirmative legal action; eligible investors may recover losses simply by remaining members of the class. Whistleblowers, former PicS employees, and others with relevant information about the Company's conduct are also encouraged to come forward.

What is a lead plaintiff, and how can I seek appointment in the PicS N.V. lawsuit?

A lead plaintiff in the PicS N.V. class action is a court-appointed investor— typically the one with the largest financial interest in the case — who directs and oversees the litigation on behalf of all class members. Any PicS investor who purchased PICS Class A common stock in or traceable to the IPO may move the Court to serve as lead plaintiff through counsel of their choice. The deadline to seek lead plaintiff appointment is August 4, 2026. Importantly, choosing not to seek the lead plaintiff role does not affect an investor's ability to share in any recovery obtained for the class.

What should investors do if they purchased PicS N.V. stock in the IPO?

Investors who purchased PicS N.V. (PICS) Class A common stock in and/or traceable to the January 30, 2026 IPO and suffered losses should contact Faruqi & Faruqi, LLP immediately to discuss their legal rights. The deadline to seek appointment as lead plaintiff in the PicS N.V. securities class action is August 4, 2026. To speak directly with securities litigation partner Josh Wilson, call 877-247-4292 or 212-983-9330 (Ext. 1310), or visit www.faruqilaw.com/PICS for more information.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/304086

Source: Faruqi & Faruqi LLP

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

July 07, 2026 16:05 ET  | Source: Itron, Inc.

LIBERTY LAKE, Wash., July 07, 2026 (GLOBE NEWSWIRE) -- Itron, Inc. (NASDAQ: ITRI), which is innovating new ways for utilities and cities to manage energy and water, announced today that it will release financial results for the quarter ended June 30, 2026 at 8:30 a.m. EDT on Tuesday, July 28, 2026. Itron management will host a conference call at 10:00 a.m. EDT to discuss the results.

Interested parties may listen to the conference call on a live webcast. The webcast, along with a supplemental presentation, may be accessed from the company’s website at Itron Investor Events & Presentations. Participants should access the webcast 10 minutes prior to the start of the call to install and test any necessary audio software. Participants can also pre-register for the webcast at any time using the link above.

A webcast replay of the conference call will be available through Aug. 4, 2026 and may be accessed on the company’s website at Itron Investor Events & Presentations.

About Itron

Itron is transforming how the world manages energy, water and city services. Our trusted intelligent infrastructure solutions help utilities and cities improve efficiency, build resilience and deliver safe, reliable and affordable service. With edge intelligence, we connect people, data insights and devices so communities can better manage the essential resources they rely on to live and thrive. Join us as we create a more resourceful world: www.itron.com.

Itron® and the Itron Logo are registered trademarks of Itron, Inc. in the United States and other countries and regions. All third-party trademarks are property of their respective owners, and any usage herein does not suggest or imply any relationship between Itron and the third party unless expressly stated.

For additional information, contact:

Itron, Inc.
Paul Vincent
Vice President, Investor Relations
512-560-1172

Stephanie Tarlton, CFA
Principal, Investor Relations
(512) 676-8365
[email protected]

Itron, Inc.

LinkedIn: www.linkedin.com/company/itronincX: https://x.com/ItronIncNewsroom: https://www.itron.com/newsroomBlog: https://blogs.itron.com

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its second quarter 2026 financial results on Monday, August 3, 2026, after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. To access the call, please dial (833) 630-2124 (U.S.) or +1 (412) 317-0651 (International) and reference the “Vertex Pharmaceuticals Second Quarter 2026 Earnings Call.”

The conference call will be webcast live and a link to the webcast can be accessed through Vertex's website at www.vrtx.com in the "Investors" section. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast. An archived webcast will be available on the company's website.

About Vertex

Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases and conditions. The company has approved therapies for cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia and acute pain, and it continues to advance clinical and research programs in these areas. Vertex also has a robust clinical pipeline of investigational therapies across a range of modalities in other serious diseases where it has deep insight into causal human biology, including IgA nephropathy, neuropathic pain, APOL1-mediated kidney disease, primary membranous nephropathy, autosomal dominant polycystic kidney disease, type 1 diabetes, generalized myasthenia gravis, and myotonic dystrophy type 1.

Vertex was founded in 1989 and has its global headquarters in Boston, with international headquarters in London. Additionally, the company has research and development sites and commercial offices in North America, Europe, Australia, Latin America and the Middle East. Vertex is consistently recognized as one of the industry's top places to work, including 16 consecutive years on Science magazine's Top Employers list and one of Fortune’s 100 Best Companies to Work For. For company updates and to learn more about Vertex's history of innovation, visit www.vrtx.com or follow us on LinkedIn, Facebook, Instagram, YouTube and X.

(VRTX-WEB)

Source: Vertex Pharmaceuticals Incorporated

Marathon Petroleum remains a top "Buy" as global refining disruptions, especially in Russia, extend the duration of elevated crack spreads. Recent Ukrainian strikes have sidelined up to a third of Russian refining capacity, supporting crack spreads at $45+ for at least 15 months. MPC is poised for ~$70/share in excess cash flow by Q3 2027, enabling aggressive buybacks and at least 10% share retirement over the next year.

7.7.2026 22:17

Index Dow Jones -0,25 % na 52925,15 b. S&P 500 -0,45 % na 7503,85 b. Nasdaq Composite -1,16 % na 25818,69 b.

Americké indexy uzavírají poklesem. Nejhůře se dařilo indexu Nasdaq Composite, který ztratil víc než procento po výprodeji polovodičových společností. Poklesy spustil propad akcií Samsung, po kvartálním reportu, který neoslnil trh. Z indexu S&P 500 ztrácel sektor průmyslu, kde Caterpillar odepisuje 5,5 % po oznámení o akvizici společnosti Skycatch. Převzetí posiluje pozici Caterpillaru, jako poskytovatele celého ekosystému pro řízení dolů. Skycatch vyvájí technologie pro sběr, zpracovaní a analýzu prostorových dat. Například zpracovává 3D modely terénu a sleduje změny na lomech. Kupní cena zatím nebyla zveřejněna. Růstem se může pochlubit sektor energií, kde firmy těží z opětovně zvýšeného napětí mezi USA a Iránem, který v Hormuzském průlivu zaútočil na tanker na zkapalněný zemní plyn. USA obnovují zákaz prodeje ropy z Iránu. V reakci stoupá cena ropy. Futures kontrakty na WTI rostou o 5 % na úroveň pod USD 72.

SpaceX (- 6,83 %) se dnes stal součástí indexu Nasdaq 100. Po připojení do indexu se objevilo hned několik investičních doporučení s perimetrem cílových cen od USD 131 do USD 800. Většina analytiků posadila cílovou cenu poblíž úrovně USD 200.

Index S&P 500 -0,45 % na 7503,85 b. Nejsilnější sektory S&P Změna Nejslabší sektory S&P Změna Energie +3 % Průmysl -1,7 % Zdravotní péče +1,6 % Informační technologie -1,6 % Reality +1,5 % Základní materiály -1 % Nejsilnější akcie S&P Změna Nejslabší akcie S&P Změna Cognizant Technology Solutions Corp (CTSH) +6,2 % Intel Corp (INTC) -9,7 % Cboe Global Markets (CBOE) +6,1 % Teradyne (TER) -9,6 % Occidental Petroleum Corp (OXY) +5,9 % Generac Holdings (GNRC) -8,5 % Gilead Sciences (GILD) +5,2 % Western Digital Corp (WDC) -7,9 % Devon Energy Corp (DVN) +5,1 % Marvell Technology (MRVL) -7,5 %
Marek Kameništiak
Fio banka, a.s.
Prohlášení

Key Takeaways Valero stock rose 88.1% in a year, beating the industry and peers Phillips 66 and Marathon Petroleum.Valero's Gulf Coast network helps source discounted heavy sour crude and produce higher-value fuels.Renewable diesel, SAF and ethanol operations expand Valero's exposure to cleaner transportation fuels. Valero Energy (VLO - Free Report) is a leading refining player with a robust network of 14 refineries located across the United States, Canada and Peru. The company has a combined throughput capacity of 3 million barrels per day and a Nelson Complexity Index of 11.5, implying that its refineries can process a wide variety of feedstock into higher-value refined products like diesel and jet fuel. VLO is also involved in the production of low-carbon fuels like renewable diesel and ethanol.

Over the past year, VLO stock has gained 88.1%, outperforming the industry’s 38.4% growth. Its peers, Phillips 66 (PSX - Free Report) and Marathon Petroleum Corporation (MPC - Free Report) , have grown 40.3% and 52.5%, respectively, during the same time frame. While price performance indicates a stock's attractiveness to some extent, it would be wiser to closely examine the company’s current business environment before offering any investment advice.

Image Source: Zacks Investment Research

Refining Business Drives Valero's StrengthValero’s Gulf Coast refining network benefits the company through feedstock sourcing and exposure to high-demand product markets. In its first-quarter earnings calls, the company mentioned that its Gulf Coast presence enabled it to take advantage of discounted heavy sour barrels and optimize the product slate at its refineries, maximizing the production of high-value products like jet fuel.

Valero’s structural advantage stems from the operational flexibility of its refineries. The company's system can process a wide range of crude qualities (heavy sour, light/medium sour, etc.) and also shift product yields between light products and distillates based on market dynamics to enhance margin capture during volatile times. Notably, its feedstock flexibility and ability to maximize heavy sour crude processing are expected to act as a tailwind into the second quarter as well.

Image Source: Valero Energy Corporation

Favorable Industry Conditions Support Refining MarginsThe macroeconomic backdrop also remains favorable. Heavy sour crude grades usually trade at a discount to the West Texas Intermediate benchmark. Crude oil prices have also softened considerably in recent weeks, closing at approximately $68.55 per barrel on July 6. This is expected to benefit VLO as it could reduce feedstock costs for the refining player, improving refining economics and supporting better margins.

Beyond favorable feedstock costs, broader industry fundamentals remain constructive. Management noted that global refining capacity remains constrained, while the demand for refined products is resilient. Moreover, low product inventories in key markets are expected to support refining fundamentals, keeping margins steady.

Expansion Beyond Traditional RefiningValero has gained meaningful exposure to renewable fuels, providing an additional revenue stream. Its ownership in the Diamond Green Diesel joint venture provides VLO with approximately 1.2 billion gallons of renewable fuels production capacity per year. The recently completed Port Arthur sustainable aviation fuel (SAF) project can upgrade up to 50% of its current renewable diesel production capacity to SAF.

In addition, VLO’s ethanol operations are benefiting from increased international demand for the fuel. Management highlighted that many countries are increasing the amount of ethanol blended into gasoline to reduce emissions and costs. Global renewable fuel mandates are incentivizing producers to include low-carbon fuels in the transportation fuel mix, thereby driving demand for ethanol.

These initiatives position Valero to capitalize on the growth of cleaner transportation fuels in the long run.

Valuation SnapshotThe valuation snapshot indicates that investors are now willing to pay a premium for Valero Energy due to the company’s strong fundamentals. This is reflected in VLO’s trailing 12-month enterprise value to EBITDA (EV/EBITDA) of 8.24x compared with the broader industry average of 5.5x. However, it is currently trading cheaper compared to its peers, PSX and MPC, which are trading at 12.69x and 11.18x trailing 12-month EV/EBITDA, respectively.

Image Source: Zacks Investment Research

Time to Bet on the Stock or Wait?Valero Energy is expected to benefit from its Gulf Coast refinery network, which provides it with feedstock flexibility and access to attractive export markets. Further, the operational flexibility of its refining system enables the company to shift product yields in response to changing market conditions, supporting profitability and improving margin capture.

Considering the backdrop, it might be wise for investors to wait for a more opportune moment to own VLO, currently carrying a Zacks Rank #3 (Hold), as the stock appears somewhat overvalued. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

PEORIA, Ill.--(BUSINESS WIRE)--RLI Corp. (NYSE: RLI) – RLI today announced the launch of its Entertainment & Amusement insurance product and the appointment of Kym Tormey as Vice President, Entertainment & Amusement, to lead the business.

"This launch reflects RLI’s continued focus on identifying opportunities to serve specialized markets through deep underwriting expertise, exceptional service and strong distribution relationships."

Share RLI’s Entertainment & Amusement product is designed to serve a broad range of businesses across the industry, including amusement parks, family entertainment centers, fairs, festivals, mobile amusements, concessionaires and similar attractions. Property and casualty coverage is available on a non-admitted basis in all 50 states.

"This launch reflects RLI’s continued focus on identifying opportunities to serve specialized markets through deep underwriting expertise, exceptional service and strong distribution relationships," said Jen Klobnak, Chief Operating Officer. "We’re excited to welcome Kym to RLI. Her extensive industry experience and proven leadership will help us deliver tailored solutions that meet the evolving needs of the entertainment and amusement marketplace."

Tormey brings more than 35 years of insurance industry experience, including nine years leading specialty entertainment and amusement insurance programs. Before joining RLI, she held leadership roles at AXA XL, XL Group, Arch Insurance Group and Royal & Sun Alliance. She will lead the strategic growth and underwriting operations of RLI’s Entertainment & Amusement business.

ABOUT RLI

RLI Corp. (NYSE: RLI) is a specialty insurer serving niche property, casualty and surety markets. The company provides deep underwriting expertise and superior service to commercial and personal lines customers nationwide. RLI’s products are offered through its insurance subsidiaries RLI Insurance Company, Mt. Hawley Insurance Company and Contractors Bonding and Insurance Company. All of RLI’s subsidiaries are rated A++ “Superior” by AM Best Company. To learn more about RLI, visit www.rlicorp.com.

More News From RLI Corp.

Key Takeaways Vertiv is benefiting from AI data center demand, higher 2026 guidance and the ThermoKey acquisition.QUBT boosted first-quarter revenues through acquisitions and strengthened its quantum technology roadmap.VRT and QUBT are positioned to benefit from AI infrastructure spending and quantum commercialization efforts. Artificial intelligence and quantum computing have taken center stage in 2026. AI-driven infrastructure spending has reached record levels, while growing government support and enterprise adoption have accelerated the commercialization of quantum technologies.

Against this backdrop, we have picked two stocks, Vertiv Holdings (VRT - Free Report) and Quantum Computing Inc. (QUBT - Free Report) , which offer compelling exposure to two of the fastest-growing technology trends of 2026 — AI infrastructure and quantum computing commercialization.

Let’s get into more detail.

AI Spending Boom Remains IntactThese trends are expected to remain intact in the second half of 2026. Leading cloud providers continue to increase investments in AI infrastructure to support rapidly growing demand for generative AI workloads. Microsoft (MSFT - Free Report) has reiterated its plans to invest about $80 billion in AI-enabled data centers in fiscal 2025, while Alphabet (GOOGL - Free Report) raised its 2025 capital expenditure guidance to approximately $85 billion, citing strong demand for AI infrastructure and cloud services. Meta Platforms (META - Free Report) has also increased its 2025 capital expenditure outlook to $64-$72 billion to expand its AI infrastructure.

Government Support Strengthens Quantum OutlookThe sustained wave of hyperscale spending is expected to support demand for advanced computing, power and cooling infrastructure well into the second half of 2026. Meanwhile, the outlook for quantum computing has received a meaningful boost from U.S. policy initiatives.

On June 22, President Donald Trump signed executive orders directing federal agencies to accelerate the commercialization and deployment of quantum computing, sensing and networking technologies, update the National Quantum Strategy, strengthen domestic quantum supply chains, expand public-private partnerships and speed up the transition to post-quantum cybersecurity. These initiatives are expected to encourage additional government and enterprise investment in the quantum ecosystem over the coming months, creating a favorable backdrop for companies developing quantum technologies.

Stocks to Buy NowVertiv: The company continues to benefit from the AI infrastructure spending boom. In first-quarter 2026, the company’s revenues rose 30% year over year, while adjusted operating margin expanded to 20.8%. Management also raised its 2026 guidance, reflecting continued strength in AI-driven data center demand. In June, Vertiv completed the acquisition of ThermoKey, expanding its liquid cooling and heat rejection capabilities for AI applications. With hyperscalers such as Microsoft, Alphabet and Meta maintaining elevated AI infrastructure investments, Vertiv is well positioned to benefit from sustained demand for power, thermal management and digital infrastructure solutions through the second half of 2026.

This Zacks Rank #2 (Buy) stock is expected to report earnings growth of 51.7% on revenue growth of 34.2% in 2026. Based on short-term price targets offered by 22 analysts, the average price target of $362.45 for Vertiv represents an increase of 20.6% from the last closing price.

Image Source: Zacks Investment Research

Quantum Computing or QCi: The company is gaining traction as demand for photonics-based quantum and sensing technologies increases. In first-quarter 2026, revenues jumped to $3.7 million from $39,000 a year ago, aided by the acquisitions of Luminar Semiconductor and NuCrypt. The company ended the quarter with approximately $1.4 billion in cash, cash equivalents and investments. Management said the acquisitions strengthen QCi's roadmap for commercial quantum computing, quantum cybersecurity and photonic technologies.

The June 22 executive orders aimed at accelerating quantum commercialization and strengthening domestic quantum capabilities could provide an additional tailwind for companies like QCi in the second half of 2026 as government and enterprise adoption continues to expand.

This stock, too, is a compelling buy right now with a Zacks Rank #2. Based on short-term price targets offered by six analysts, the average price target of $18.33 for QCi represents an increase of 95.62% from the last closing price.

You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Image Source: Zacks Investment Research

Like most other up-and-coming biopharma companies, CRISPR Therapeutics (CRSP 2.10%) brings both risk and reward to the table. This particular name, however, may bring less risk than it seems at first blush, and perhaps even more reward.

CRISPR Therapeutics is different from most of its kind CRISPR Therapeutics is a developer of gene therapies for disease, by the way. Specifically, the company's founders figured out how to cut a damaged segment out of a DNA strand and replace it with a corrected one. It even has an approved therapy on the market, with more in the works.

As you might imagine, though, such development isn't cheap. Like other newcomers to the biopharma business, CRISPR Therapeutics is consuming cash at a pretty brisk clip.

Image source: Getty Images.

However, it's different from most others of this ilk. Unlike its similarly sized and similarly aged peers, this $5.9 billion outfit is sitting on $2.4 billion worth of cash and marketable securities that can be readily converted into cash if and when the need arises. At its current rate of cash burn, that's a little over four years' worth of funding without the need for any additional, dilutive fund-raising.

This essentially means the company's science, research, and future are currently valued at only about $3.5 billion, or only around $3 billion after factoring in debt.

The stock price reflects too much risk with not enough reward Granted, CRISPR Therapeutics needs at least some of its current research and development pipeline to result in drug approvals to justify any valuation. And to raise money, the company has issued stock and convertible notes before, which of course was dilutive.

Today's Change

(

-2.10

%) $

-1.30

Current Price

$

60.59

All of this is already priced into the stock, though, and won't need to happen again anytime soon -- if ever. See, CRISPR Therapeutics has the potential to generate its own self-sustaining funding within just a few years. The odds of this happening aren't reflected in the current share price.

Analysts don't think so, anyway. Their current consensus price target of $81.10 is 35% above the price right now.